Inotrem announces the publication of its Phase IIa clinical study for nangibotide in the treatment of septic shock in peer review journal "Intensive Care Medicine"

Intensive Care Medicine publishes the results of Inotrem's study which demonstrated the safety and tolerability of its lead compound, nangibotide, in patients suffering from septic shock.

Paris (France). June 2nd. 2020. Inotrem S.A., a biotechnology company specializing in immunotherapy for acute inflammatory syndromes, through its knowledge of the TREM-1 pathway biology, announced today that peer review journal *Intensive Care Medicine* has published the results of its Phase IIa study which demonstrated the safety and tolerability of its lead compound in patients suffering from septic shock. The article "Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial" is accessible via the following link: https://rdcu.be/b4tCV

The study conducted in 2018 was an 11-months multicenter phase IIa clinical trial with 49 patients suffering from septic shock enrolled in four European countries (Belgium, France, The Netherlands and Spain). The results bring positive data on the safety and tolerability of Inotrem's lead product candidate, nangibotide, in septic shock patients. The study also showed that nangibotide treated patients with soluble TREM-1 levels above median at entry displayed a consistent signal toward a more favorable evolution of biological and clinical activity markers. These results support Inotrem's personalized medicine approach: using soluble TREM-1 level in blood as a potential biomarker for the identification of patients who will most likely benefit from nangibotide treatment.

Following these positive results, Inotrem has launched in November 2019 its Phase IIb ASTONISH study which aims to demonstrate the efficacy of nangibotide and bring a medically relevant proof of clinical activity in septic shock patients. The study is being conducted in 48 clinical sites across 5 European countries and the United States and will enroll a total number of 450 patients.

Jean-Jacques Garaud, CEO of Inotrem, said: *"This publication in such a highly recognized peer review journal as Intensive Care Medicine demonstrates the quality of our research on the TREM-1 pathway, and validates the strong potential of our lead compound, nangibotide, in the treatment of inflammatory syndromes and more specifically in septic shock patients".*

With nangibotide, Inotrem has developed a novel approach of immunomodulation targeting the TREM-1 pathway which has the potential to address, beyond septic shock, several others acute inflammatory syndromes for which there is a major and today unsatisfied therapeutic need.

About Inotrem

Inotrem S.A. is a biotechnology company specialized in immunotherapy for acute and chronic inflammatory syndromes. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses. The company was founded in 2013 by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive. Inotrem is supported by leading European and North American investors.
www.inotrem.com

About Nangibotide

Nangibotide is the formulation of the active ingredient LR12, which is a 12 amino-acid peptide prepared by chemical synthesis. LR12 is a specific TREM-1 inhibitor, acting as a decoy receptor and interfering in the binding of TREM-1 and its ligand. In preclinical septic shock models, nangibotide was able to restore appropriate inflammatory response, vascular function, and improved animals' survival post septic shock. Nangibotide in septic shock has been granted the fast track status in September 2019 by the FDA.

Media contact for Inotrem
Anne REIN
S&I
anne.rein@strategiesimage.com
+33 6 03 35 92 05